Comprehensive review article on adaptive immunity in GU Cancers led by @CanImmun @tbivala1 @pcvblack @MattGalsky @ImmunoBladder @IBCG_BladderCA @IBCN1997 #bladdercancer

Long awaited data from @SWOG 1011 investigating value of ELND in MIBC 👉no diff in DFS w ELND 👉more LN yield 👉more SAE w ELND 👉? benefit in pT3/4 Congrats to Dr. Seth Lerner and the entire team 👏👏👏 #ASCO23

Honored to discuss @ASCO (pinch hitting for @UroDocAsh ) S1011 trial results demonstrating NO DFS/OS for EPLND @slernerbcmedu1 concludes that SLND is now standard of care for T2-T4N0 patients undergoing RC. >LN counts, >morbidity. Predominantly T2 cohort with 57%NAC!

@tbivala1 give his take home messages for the 1] #SWOGS1011 surgical trial of standard vs extended lymphadenectomy 2] the #VESPER trial of dd-MVAC vs GC as perioperative chemo for MIBC 3] #CheckMate914 Adjuvant Nivo/Ipi in high risk #RCC after nephrectomy @ASCO #ASCO23

@UrogerliMD @UroDocAsh @tbivala1 @cgoncology Outstanding combo replication selective cretostimogene plus checkpoint inhibitor Proof of principle and improving patient outcomes with very high NMIBC #gdsfellows @bcan_chisolm

Updated results from #CORE1 using pembro + cretostimogene (cg0070) in BCG unresponsive CIS 👉 Overall CR = 85% (29/34) 👉CR @ 12 months = 68% (17/25) 👉AE profile similar to monotherapy trials @garysteinbergmd @UroDocAsh @tbivala1 @cgoncology https://t.co/9jvfxWkzcs

The hap-hap-happiest time of the year! The two jolliest elves this side of the nuthouse!!

Intermediate-risk Non–muscle-invasive BC: Updated Consensus Definition and Management Recommendations from the International BC Group https://t.co/Kiu8F6sjcu @drtanws @garysteinbergmd @UrogerliMD @DrShariat @MRoupret @tbivala1 @spsutkaMD @SWilliams_MD @uromc @UroDocAsh

#urotwitter What are the 50 Landmark papers urologists should know? for a new @CRCPress book. These can be a new procedure, evaluating effects of new treatments/techniques, new classification system or insights into disease. With great coauthors @ClaireJTaylor1 @Yasminabugh

Former @brady_urology co-residents caught out in the wild 🤙 👍 #AUA22

Congrats to my past mentee @MeeraChappidi and current mentee @ridwanalam_ on their much deserved grants from the @UrologyCareFdn

@brady_urology @aloksinghjnu @8Monali Work done in the @tbivala1 lab

@brady_urology @aloksinghjnu @8Monali @tbivala1

A new candidate vaccine against NMIBC in a multi institutional study in close collaboration with @tbivala1 Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against…

@MaxKates @Svet_MD @brady_urology @tbivala1 @ClaireDlc Could not agree more. These in addition to publication by @KKBree, highlighting the importance of changing the dogma in female cystectomies.

Huge momentum thx to @Svet_MD addressing organ preservation in women. Long history of this @brady_urology, recent pub by @SHPatelMD1 @tbivala1: https://t.co/4LGD2JZ9wp Now doing organ pres with opportunistic salpingectomy. More data needed https://t.co/TDgxQJD4Iq @ClaireDlc

A Molecular Inquiry into the Role of Antibody-Drug Conjugates in Bacillus Calmette-Guérin-exposed Non–muscle-invasive Bladder Cancer https://t.co/JlWgJgRZa4 @MaxKates @kara_lombardo @Andres_Matoso @urogabe @JCensits @djmcconkey @tbivala1 @Andres_Matoso

Always enjoy sharing the annual @AmerUrological Early Career Investigators Workshop class & faculty! So grateful to our dedicated faculty and congratulations to all of our early career investigators for making this commitment to your research funding success! @MaleHealthDoc

Starting now: Day 2 #AIBCCR On program: Targeting Metastatic Disease @WilliamKimMD et al BCG and beyond @ImmunoBladder @MaxKates @tbivala1 @JoshMeeks @garysteinbergmd